J. Scavone, R. Gleckman, D. G. Fraser
Sep 10, 1982
Citations
0
Influential Citations
8
Citations
Journal
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
Abstract
Cinoxacin, a chemotherapeutic agent that inhibits bacterial DNA synthesis, has recently been approved for the treatment of initial and recurrent bacterial urinary tract infections. Although closely related to nalidixic acid, cinoxacin possesses some distinct characteristics: rapid attainment of therapeutic urinary concentrations and greater activity against strains of Enterobacteriaceae that cause urinary tract infections. Biopharmaceutical properties include serum protein binding of approximately 70%, 50–60% excretion of intact drug in the urine of patients with normal renal function, and an elimination half‐life of approximately one hour. The elimination half‐life is increased in patients with decreased renal function and when probenecid is coadministered.